Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States

Vaccine

Volumn 31, Issue 29, 2013, Pages 3019-3024

  Chesson, Harrell W ^a   Flagg, Elaine W ^a   Koutsky, Laura ^b   Hsu, Katherine ^c   Unger, Elizabeth R ^a   Shlay, Judith C ^d   Kerndt, Peter ^e   Ghanem, Khalil G ^f   Zenilman, Jonathan M ^f   Hagensee, Michael ^g   Weinstock, Hillard ^a   Datta, S Deblina ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

^d DENVER PUBLIC HEALTH   (United States)

^e Los Angeles Department of Health Services   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

HPV; HPV vaccine; Papanicolaou test; Vaccination effects

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; DIAGNOSTIC ERROR; FAMILY PLANNING; GROUPS BY AGE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MATHEMATICAL MODEL; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROBABILITY; RISK FACTOR; SEXUALLY TRANSMITTED DISEASE; UNITED STATES;

ADOLESCENT; ADULT; CHILD; EPIDEMIOLOGICAL MONITORING; FEMALE; HUMANS; INCIDENCE; MODELS, IMMUNOLOGICAL; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREGNANCY; PREVALENCE; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 84879011881     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.051     Document Type: Article

References (28)

1. Sanders G.D., Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003, 9(1):37-48.
2. Taira A.V., Neukermans C.P., Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004, 10(11):1915-1923.
3. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004, 96(8):604-615.
4. Kulasingam S.L., Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003, 290(6):781-789.
5. Elbasha E.H., Dasbach E.J., Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007, 13(1):28-41.
6. Kim J.J., Goldie S.J. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359(8):821-832.
7. Chesson H.W., Forhan S.E., Gottlieb S.L., Markowitz L.E. The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine 2008, 26(35):4513-4518.
8. Brisson M., Van de Velde N., Boily M.C. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genom 2009, 12(5/6):343-351.
9. Goldie S.J., Grima D., Kohli M., Wright T.C., Weinstein M., Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003, 106(6):896-904.
10. Insinga R.P., Glass A.G., Myers E.R., Rush B.B. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making 2007, 27(4):414-422.
11. Henk H.J., Insinga R.P., Singhal P.K., Darkow T. Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population. J Low Genit Tract Dis 2010, 14(1):29-36.
12. Insinga R.P., Glass A.G., Rush B.B. The health care costs of cervical human papillomavirus - related disease. Am J Obstet Gynecol 2004, 191(1):114-120.
13. Datta S.D., Koutsky L.A., Ratelle S., Unger E.R., Shlay J., McClain T., et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann Intern Med 2008, 148(7):493-500.
14. Gaffga N.H., Flagg E.W., Weinstock H.S., Shlay J.C., Ghanem K.G., Koutsky L.A., et al. Monitoring HPV type-specific prevalence over time through clinic-based surveillance: a perspective on vaccine effectiveness. Vaccine 2012, 30(11):1959-1964.
15. Dorell C., Stokley S., Yankey D., Liang J.L., Markowitz L. National and state vaccination coverage among adolescents aged 13 through 17 years - United States, 2010. MMWR Morb Mortal Wkly Rep 2011, 60(33):1117-1123.
16. Castellsague X., Munoz N., Pitisuttithum P., Ferris D., Monsonego J., Ault K., et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011, 105(1):28-37.
17. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199(7):926-935.
18. Cuzick J., Castanon A., Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br J Cancer 2010, 102(5):933-939.
19. Dietsch E., Gibb H., Francis K. Abnormal Pap test results and the rurality factor. Aust J Rural Health 2003, 11(2):50-56.
20. Shinn E., Basen-Engquist K., Le T., Hansis-Diarte A., Bostic D., Martinez-Cross J., et al. Distress after an abnormal Pap smear result: scale development and psychometric validation. Prev Med 2004, 39(2):404-412.
21. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103(19):1444-1451.
22. Romanowski B., Schwarz T.F., Ferguson L.M., Peters K., Dionne M., Schulze K., et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: results from a randomized study. Hum Vaccine 2011, 7(12):1374-1386.
23. Bogaards J.A., Coupe V.M., Xiridou M., Meijer C.J., Wallinga J., Berkhof J. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011, 22(4):505-515.
24. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer Cytopathol 2007, 111(3):145-153.
25. Jit M., Choi Y.H., Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008, 337:a769.
26. Watson M., Saraiya M., Ahmed F., Cardinez C.J., Reichman M.E., Weir H.K., et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer 2008, 113(10 Suppl.):2841-2854.
27. Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012, 137(4):516-542.
28. Markowitz L.E., Hariri S., Unger E.R., Saraiya M., Datta S.D., Dunne E.F. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010, 28(30):4731-4737.